Original Research

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England

Meng J, Lister J, Vataire AL, Casciano R, Dinet J

ClinicoEconomics and Outcomes Research 2018, 10:243-250

Published Date: 23 April 2018